Active Filter(s):
Details:
APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.
Lead Product(s): APL-102
Therapeutic Area: Oncology Product Name: APL-102
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2021